| Figure 9. |
|
|
| Capitalized clinical period cost per approved NCE (7). The all category results cover the full sample of 93 NCEs. Data are for a sample of NCEs that first entered clinical testing anywhere in the world during 1970 to 1982. Costs were deflated using the GDP Implicit Price Deflator. A 9% real discount rate was used to capitalize out-of-pocket cost per approved NCE. Time cost is a measure of the income forgone from investing in development for a period before returns are earned. Total is the sum of out-of-pocket and time cost. |
published 2000